艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADC 艾格里房产

休市中 01-09 16:00:00 EST

70.51

-0.30

-0.42%

盘后70.51

+0.000.00%

19:43 EST

最高71.12	最低69.56	成交量170.53万
今开70.56	昨收70.81	日振幅2.20%
总市值81.04亿	流通市值76.41亿	总股本1.15亿
成交额1.20亿	换手率1.57%	流通股本1.08亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房产","latestPrice":70.51,"timestamp":1767992400000,"preClose":70.81,"halted":0,"volume":1705251,"hourTrading":{"tag":"盘后","latestPrice":70.51,"preClose":70.51,"latestTime":"19:43 EST","volume":34387,"amount":2424614.969,"timestamp":1768005808828},"delay":0,"floatShares":108366822,"shares":114934390,"eps":1.712089,"marketStatus":"休市中","change":-0.3,"latestTime":"01-09 16:00:00 EST","open":70.56,"high":71.12,"low":69.56,"amount":119978271.54063,"amplitude":0.022031,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.712089,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":70.81,"dividendRate":0.043313,"preHourTrading":{"tag":"盘前","latestPrice":70.71,"preClose":70.81,"latestTime":"09:29 EST","volume":34,"amount":2407.17365,"timestamp":1767968999008},"postHourTrading":{"tag":"盘后","latestPrice":70.51,"preClose":70.51,"latestTime":"19:43 EST","volume":34387,"amount":2424614.969,"timestamp":1768005808828},"volumeRatio":0.9921481145264572,"impliedVol":0.2194,"impliedVolPercentile":0.4622},"requestUrl":"/m/hq/s/ADC","defaultTab":"news","newsList":[{"id":"2601562331","title":"港股异动 | 复宏汉霖(02696)盘中涨超5% 公司首次公布PD-L1 ADC食管鳞状细胞癌Ⅱ期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2601562331","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601562331?lang=zh_cn&edition=full","pubTime":"2026-01-08 11:18","pubTimestamp":1767842338,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖盘中涨超5%，截至发稿，涨4.39%，报66.65港元，成交额2390.53万港元。其中，复宏汉霖首次公布其PD-L1 ADC药物HLX43治疗复发/转移性食管鳞状细胞癌中的临床数据。HLX43是靶向PD-L1的新型ADC药物，兼具免疫检查点抑制与细胞毒性双重作用，其I期临床已证实对免疫治疗无效患者具有前景疗效和良好耐受性。本项Ⅱ期研究旨在评估HLX43用于经治复发 / 转移性食管鳞状细胞癌患者的疗效与安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK4231","ADC","BK4023","HK0000165453.HKD","02696","BK1161","LU1169590202.USD","LU1169589451.USD","PD"],"gpt_icon":0},{"id":"2601186053","title":"百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于治疗复发性或转移性食管鳞癌被纳入优先审评程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2601186053","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601186053?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:53","pubTimestamp":1767689624,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，近日，公司自主研发的全球首创(First-in-class)、新概念(New concept)且唯一进入III期临床阶段的EGFR×HER3双抗ADC(注射用iza-bren)被国家药品监督管理局药品审评中心(简称“CDE”)纳入优先审评品种名单。根据公开资料查询，iza-bren也是全球首个被纳入优先审评品种名单的EGFR×HER3双抗ADC。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","BK4080","688506","BK0239","91194","02615","BK4231"],"gpt_icon":0},{"id":"2601020061","title":"科伦博泰生物-B(06990)核心产品TROP2 ADC芦康沙妥珠单抗(SAC-TMT)联合免疫疗法帕博利珠单抗一线治疗PD-L1阳性局部晚期或转移性非小细胞肺癌获NMPA突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2601020061","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601020061?lang=zh_cn&edition=full","pubTime":"2026-01-05 08:01","pubTimestamp":1767571299,"startTime":"0","endTime":"0","summary":"此前，公司公布了芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阳性NSCLC的3期OptiTROP-Lung05临床试验结果，其在主要终点无进展生存期显示出统计学意义和临床意义的显著改善，并在总生存期方面观察到获益趋势。OptiTROP-Lung05研究是首个免疫联合ADC在一线治疗NSCLC上达到主要终点的3期临床研究。此次在一线治疗PD-L1阳性NSCLC获得突破性疗法认定，将为加速芦康沙妥珠单抗在此适应症审评与上市进程提供助力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388399.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","LU1169590202.USD","BK4080","LU0196878994.USD","LU1169589451.USD","BK4231","BK4023","PD","ADC","BK1161"],"gpt_icon":0},{"id":"2600040163","title":"科伦博泰生物-B(06990)：ITGB6 ADC SKB105新药临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2600040163","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600040163?lang=zh_cn&edition=full","pubTime":"2026-01-04 19:59","pubTimestamp":1767527952,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B 发布公告，公司自主研发的靶向整合素β6抗体偶联药物SKB105的新药临床试验申请已获中国国家药品监督管理局药品审评中心批准，用于治疗晚期实体瘤。公司计划于近期向中国国家药品监督管理局药品审评中心递交SKB118/CR-001的IND申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","06990","BK1161","BK4080","BK4231","ADC"],"gpt_icon":0},{"id":"2600056352","title":"港股异动 | 恒瑞医药(01276)午后涨超5% CLDN18.2 ADC胃癌适应症纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2600056352","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600056352?lang=zh_cn&edition=full","pubTime":"2026-01-02 13:43","pubTimestamp":1767332632,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药午后涨超5%，截至发稿，涨5.19%，报74.95港元，成交额5568.71万港元。消息面上，恒瑞医药宣布，其自主研发的靶向Claudin18.2的抗体药物偶联物——注射用SHR-A1904，已被国家药品监督管理局药品审评中心正式纳入突破性治疗品种名单。该药物拟用于治疗既往接受过至少一线系统治疗的CLDN18.2阳性的局部晚期或转移性胃或胃食管交界处腺癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1146622755.USD","LU1820825898.SGD","LU0405327494.USD","BK0060","BK0188","LU2097828474.EUR","LU2543165471.USD","LU1255011170.USD","LU1064131003.USD","LU2289578879.USD","BK0196","LU1781817850.SGD","LU0359201885.HKD","LU2097828714.EUR","LU0359202008.SGD","01276","LU2328871848.SGD","LU0405327148.USD","LU2580892862.HKD","LU2097828805.USD","BK0183","BK4080","LU0359201612.USD","LU2495084118.USD","LU1969619763.USD","BK4231","BK0028","LU2097828631.EUR","BK0239","BK0012","LU1023057109.AUD","BK1191","LU2097828557.USD","LU1997245177.USD","LU1064130708.USD","LU1997244956.HKD","LU1997245094.SGD","LU1580142542.USD","LU1655091616.SGD","LU2148510915.USD","600276","LU2488822045.USD","ADC","LU1328615791.USD","LU2580892789.USD"],"gpt_icon":0},{"id":"2595588735","title":"健玛生物终止一款在研抗癌疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2595588735","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595588735?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:11","pubTimestamp":1767017460,"startTime":"0","endTime":"0","summary":"丹麦药企健玛生物周一宣布，将终止一款已进入后期临床试验的在研抗体抗癌疗法的研发工作。　　2024 年，百欧恩泰决定不再继续开展该疗法的研究后，健玛生物便独家接手了阿卡萨利单抗的研发及潜在商业化工作。　　健玛生物将把研发资源集中至埃普金利单抗、佩托森他单抗和利纳他巴特 - 塞苏替康等同样处于后期研发阶段的抗癌疗法项目。　　健玛生物补充称，终止阿卡萨利单抗研发的决定，不会影响公司 2025 年全年业绩预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-29/doc-inhenrqi0052363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4080","BK4231","ADC"],"gpt_icon":0},{"id":"2595784785","title":"新股消息 | 百力司康港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2595784785","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595784785?lang=zh_cn&edition=full","pubTime":"2025-12-29 19:16","pubTimestamp":1767006987,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，BlissBio Inc.(简称：百力司康)于6月29日递交的港股招股书满6个月，于12月29日失效，递表时高盛、华泰国际及建银国际为联席保荐人。招股书显示，百力司康是一家处于临床阶段的生物制药公司，致力于开发下一代抗体偶联药物(ADC)，以解决目前肿瘤治疗中重要的未满足的需求。公司核心产品BB-1701(核心产品)是一种人类表皮生长因子受体2(HER2)靶向型艾立布林ADC候选药物，主要针对乳腺癌(BC)、非小细胞肺癌(NSCLC)和潜在的其他HER2表达癌症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","BK4080","BK4231","BC","BK4190"],"gpt_icon":0},{"id":"2594233412","title":"阿斯利康与第一三共ADC抗癌药在华获批第五项适应证","url":"https://stock-news.laohu8.com/highlight/detail?id=2594233412","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594233412?lang=zh_cn&edition=full","pubTime":"2025-12-25 16:43","pubTimestamp":1766652224,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4568","LU2236285917.USD","LU0320765992.SGD","LU0889565916.HKD","LU1829250122.USD","BK4231","LU2417539215.USD","AZN","LU2456880835.USD","LU2462157665.USD","BK4080","BK4588","ADC","LU0109394709.USD","BK4007","BK4585"],"gpt_icon":0},{"id":"2593869497","title":"医药巨头年末杀疯了：25亿美元买渐冻症药物，10.6亿美元ADC出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2593869497","media":"MedTrend医趋势","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593869497?lang=zh_cn&edition=full","pubTime":"2025-12-23 19:44","pubTimestamp":1766490240,"startTime":"0","endTime":"0","summary":"盐野义方面表示，预计该交易将于2026年4月1日或之后完成交割，交易完成后每年将为公司新增约7亿美元的全球销售额。根据官方披露，盐野义将以25亿美元的一次性付款方式收购Radicava相关业务，同时约定在“特定条件”下支付潜在的未来特许权使用费。交易交割后，Radicava业务单元将成为盐野义的全资子公司。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2025-12-23/doc-inhcuyui5237827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4080","BK4231","BK1515","BK1574","BK1161","09939","159938","ADC"],"gpt_icon":0},{"id":"2592736909","title":"“港股BD之王”拿大单，金额或超11亿美元！股价不涨反跌，公司：大部分收入明年确认","url":"https://stock-news.laohu8.com/highlight/detail?id=2592736909","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592736909?lang=zh_cn&edition=full","pubTime":"2025-12-18 15:49","pubTimestamp":1766044151,"startTime":"0","endTime":"0","summary":"在今年先后宣布与阿斯利康、日本制药巨头大冢制药达成合作后，和铂医药-B（02142.HK）再度宣布与百时美施贵宝（BMS）的合作。12月17日，和铂医药发布公告称，公司与百时美施贵宝达成长期全球战略合作及许可协议，双方将共同研发新一代多特异性抗体疗法。根据协议条款，和铂医药将与百时美施贵宝合作推进及加速多特异性抗体发现项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512183595419049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","BMS","02142","BK4080","BK4231","ADC","BK1583"],"gpt_icon":0},{"id":"2591982690","title":"科伦博泰生物与宜联生物达成和解 后者6款ADC管线收入需按比例分成","url":"https://stock-news.laohu8.com/highlight/detail?id=2591982690","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591982690?lang=zh_cn&edition=full","pubTime":"2025-12-16 20:57","pubTimestamp":1765889874,"startTime":"0","endTime":"0","summary":"12月16日，科伦博泰生物（06990）发布公告，公司与苏州宜联生物医药有限公司及相关人士订立和解协议，以解决公司对宜联生物方提起的若干争议。该争议涉及2024年对宜联生物方的刑事控告以及2025年对其涉嫌侵犯商业秘密和损害公司利益的民事诉讼。为了节省与法律程序相关的时间和成本，公司与宜联生物方经过磋商达成和解。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163593237226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4231","BK4080","ADC"],"gpt_icon":0},{"id":"2590552722","title":"【券商聚焦】交银国际上调康宁杰瑞制药(09966)评级至买入 看好其ADC产品矩阵的巨大全球市场潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2590552722","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590552722?lang=zh_cn&edition=full","pubTime":"2025-12-11 09:06","pubTimestamp":1765415190,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，康宁杰瑞制药 HER2双抗ADC管线加速推进，糖基定点偶联平台持续验证：JSKN003正在进行/即将启动多项注册临床，包括2L HER2+ BC、≥2L HER2低表达BC、PROC和HER2+ CRC。JSKN016单药在TNBC中显示出优异疗效，并正在一项针对晚期NSCLC的Ib期研究中探索与卡铂、伏美替尼、及依沃西单抗等药物的联用方案，预计相关数据将于2026年公布。该机构看好公司ADC产品矩阵的巨大全球市场潜力，上调2025-27年收入预测3-8%、上调DCF目标价至13.0港元、上调评级至买入。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971330","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","09966"],"gpt_icon":0},{"id":"2590394122","title":"新股前瞻|布局TCE肿瘤疗法千亿蓝海，时迈药业能否博得市场青睐？","url":"https://stock-news.laohu8.com/highlight/detail?id=2590394122","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590394122?lang=zh_cn&edition=full","pubTime":"2025-12-09 13:05","pubTimestamp":1765256702,"startTime":"0","endTime":"0","summary":"近日，又一创新药企正式向港交所提交上市申请。在此背景下，作为一家专注于实体瘤TCE疗法、且具备多款全球前列临床管线的企业，时迈药业的上市进程亦自然备受瞩目。布局TCE疗法 四款创新药物处于临床阶段智通财经APP了解到，时迈药业目前仍处于临床研发阶段，并无产品商业化。根据时迈药业招股书披露，当前仅有两款用于实体瘤的TCE药物获得全球批准，市场存在大量空白，这为具备相关布局能力的创新药企提供了结构性机遇。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","IE00B19Z4B17.USD","IE0031619046.USD","IE00B7SZL793.SGD","CRS","BK4107","L","LU0210528500.USD","ORR","IE00B66KJ199.SGD","LU0963586101.USD","BK4585","LU0053666078.USD","BK4187","BK4006","ADC","BK4588","LU2065731478.USD","BK4080","LU2487616109.SGD"],"gpt_icon":0},{"id":"2589289437","title":"ADC药物与PD-1/VEGF双抗联用再添案例 科伦博泰与Crescent达成双向授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2589289437","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589289437?lang=zh_cn&edition=full","pubTime":"2025-12-05 19:52","pubTimestamp":1764935561,"startTime":"0","endTime":"0","summary":"12月4日，科伦博泰（HK06990）与CrescentBiopharma,Inc.（一家纳斯达克上市公司，以下简称Crescent）共同宣布，双方已建立战略合作伙伴关系。科伦博泰方面将ADC药物（抗体偶联药物）SKB105在中国以外权利授权Crescent，并预计将获得最高超13亿美元的授权收入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512053584015760.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512053584015760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4080","LU1169590202.USD","LU1169589451.USD","PD","BK4023","BK4231"],"gpt_icon":0},{"id":"2589448869","title":"港股异动 | 百奥赛图-B(02315)涨超3% 授权IDEAYA双抗ADC项目IDE034获FDA IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589448869","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589448869?lang=zh_cn&edition=full","pubTime":"2025-12-05 14:46","pubTimestamp":1764917191,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B涨超3%，截至发稿，涨2.84%，报31.86港元，成交1299.1万港元。IDEAYA预计将在2026年第一季度开始患者入组，初步评估B7H3和PTK7共表达的实体瘤类型，包括肺癌、结直肠癌、头颈癌及卵巢/妇科肿瘤。此外，IDEAYA计划探索IDE034与其PARG抑制剂IDE161的联合治疗策略，以增强疗效持续性，并计划在2026年上半年重要医学会议上分享更多支持PARG与TOP1 ADC联合治疗机制的数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","ADC","IND","BK4231","688796","BK1161","02315"],"gpt_icon":0},{"id":"2589865213","title":"ADC与PD-1红海之外，宝济药业如何找到生物医药的“第二增长曲线”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589865213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589865213?lang=zh_cn&edition=full","pubTime":"2025-12-05 13:33","pubTimestamp":1764912788,"startTime":"0","endTime":"0","summary":"而在ADC、PD-1等热门靶点赛道数百家企业拥挤厮杀，从临床入组速度到未来的市场定价无不白热化的竞争中，上海宝济药业股份有限公司选择了一条截然不同的差异化战略路径。与传统疗法相比，KJ103的革命性优势则在于其“快”。目前，其领先地位和临床价值已获得监管机构的高度认可。对于KJ017而言，其市场空间并不取决于自身的销量，而是与整个千亿级生物药市场的增长深度绑定，其商业模式堪称典型的“卖水人”逻辑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK4231","LU1169590202.USD","PD","BK4080","161726","LU1169589451.USD","BK4023","399441","ADC"],"gpt_icon":1},{"id":"2588709367","title":"复宏汉霖PD-L1 ADC II期结果读出；*ST苏吴进入退市整理期｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2588709367","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588709367?lang=zh_cn&edition=full","pubTime":"2025-12-02 07:01","pubTimestamp":1764630081,"startTime":"0","endTime":"0","summary":"丨2025年12月2日星期二丨NO.1复宏汉霖PD-L1ADCII期结果读出11月26日，复宏汉霖发布公告表示将在ESMOAsia2025大会上公布多项药物的临床数据。亮点之一在于核心资产PD-L1ADC药物HLX43在宫颈癌领域的II期研究结果。点评：针对PD-L1ADC开发在研管线并不多，目前进度最快的是辉瑞的PF-08046054，已至临床III期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512023579600777.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023579600777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","BK4231","PD","02696","LU1169589451.USD","159938","600200","LU1169590202.USD","BK4023","BK1515","HK0000165453.HKD","BK1574","BK0028","BK4080","BK0012","BK0188","BK0060","BK1161","ADC","BK0239"],"gpt_icon":0},{"id":"2586389271","title":"兴证国际：首予映恩生物-B(09606)“增持”评级 公司立足创新持续引领下一代ADC研发浪潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2586389271","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586389271?lang=zh_cn&edition=full","pubTime":"2025-11-28 09:08","pubTimestamp":1764292136,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，兴证国际发布研报称，首次覆盖，给予映恩生物-B“增持”评级，映恩生物聚焦 ADC 赛道领域，借助与 BioNTech 等全球领先药企的合作，以中国速度推进全球多中心临床快速布局，在 ADC 领域占据有利的竞争身位。兴证国际主要观点如下：近期事件2025 年 10 月 23 日公司举办研发日，介绍公司 ADC 产品管线近期进展以及未来发展方向。2025 年 11 月 14 日公司自身免疫 ADC 产品管线 DB-2304用于系统性红斑狼疮临床全球 1/2a期研究的 2a 期部分完成首例患者给药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06058","09606","ADC"],"gpt_icon":0},{"id":"2586428185","title":"港股异动 | 中国生物制药(01177)涨超4% 旗下正大晴天自研HER2双抗ADC新辅助治疗乳腺癌取得重要突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2586428185","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586428185?lang=zh_cn&edition=full","pubTime":"2025-11-26 10:28","pubTimestamp":1764124108,"startTime":"0","endTime":"0","summary":"消息面上，11月25日，注射用TQB2102单药用于HER2阳性乳腺癌新辅助治疗的Ⅱ期临床研究结果，获国际著名期刊《临床肿瘤学杂志》 在线发表。TQB2102是中国生物制药旗下正大天晴自主研发的一种靶向HER2两个非重叠表位ECD2及ECD4的抗体偶联药物。该项研究由复旦大学附属肿瘤医院邵志敏教授团队领衔，为首个证实双表位HER2 ADC TQB2102在乳腺癌新辅助治疗阶段具有良好疗效和安全性的研究，Ⅲ期注册临床研究正在开展中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1521","BK1191","BK4231","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","HK0000165453.HKD","ADC","IE00BZ08YR35.GBP","BK1589","BK4080","01177"],"gpt_icon":0},{"id":"2586341050","title":"港股异动 | 和铂医药-B(02142)涨近5% 与阿斯利康进一步拓展合作范围 开发ADC及T细胞衔接器疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2586341050","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586341050?lang=zh_cn&edition=full","pubTime":"2025-11-25 10:23","pubTimestamp":1764037381,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B(02142)涨近5%，截至发稿，涨4.92%，报13.62港元，成交额1542.11万港元。消息面上，11月24日，和铂医药-B发布公告，有关公司的间接全资附属公司和铂医药(上海)有限责任公司(和铂上海)与AstraZeneca PLC (AstraZeneca)订立合作、选择权及许可协议，于2025年11月24日，经修订和铂上海与 AstraZeneca订立的合作协议后，订约双方的合作范围进一步扩展，旨在结合两家公司的专业知识，共同发现及开发包括抗体偶联药物(ADC)及T细胞衔接器在内的新一代生物疗法。经济条款与合作协议项下建立的财务框架仍然一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","LU2417539215.USD","LU0109394709.USD","LU0320765992.SGD","BK1161","LU2236285917.USD","BK4231","LU0889565916.HKD","BK4007","BK1583","02142","BK4080","BK4568","LU2456880835.USD","ADC","BK1574","AZN","LU1829250122.USD","LU2462157665.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0105},{"period":"3month","weight":-0.0221},{"period":"6month","weight":-0.0155},{"period":"1year","weight":0.0118},{"period":"ytd","weight":-0.0211}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agree Realty Corporation成立于1971年，是马里兰州的一家公司。该公司是一家完全整合的房地产投资信托基金，主要专注于净出租给行业领先租户的零售物业的所有权、收购、开发和管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":-0.004325},{"month":2,"riseRate":0.451613,"avgChangeRate":-0.001428},{"month":3,"riseRate":0.580645,"avgChangeRate":0.015289},{"month":4,"riseRate":0.580645,"avgChangeRate":0.002795},{"month":5,"riseRate":0.5,"avgChangeRate":0.015633},{"month":6,"riseRate":0.65625,"avgChangeRate":0.010123},{"month":7,"riseRate":0.65625,"avgChangeRate":0.022845},{"month":8,"riseRate":0.46875,"avgChangeRate":0.002201},{"month":9,"riseRate":0.46875,"avgChangeRate":-0.006321},{"month":10,"riseRate":0.5625,"avgChangeRate":-0.000339},{"month":11,"riseRate":0.65625,"avgChangeRate":0.003584},{"month":12,"riseRate":0.46875,"avgChangeRate":0.00994}],"exchange":"NYSE","name":"艾格里房产","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾格里房产,ADC,艾格里房产股票,艾格里房产股票老虎,艾格里房产股票老虎国际,艾格里房产行情,艾格里房产股票行情,艾格里房产股价,艾格里房产股市,艾格里房产股票价格,艾格里房产股票交易,艾格里房产股票购买,艾格里房产股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}